@article{8105,
  keywords = {Adult, Animals, Anti-Bacterial Agents, Aza Compounds, Fluoroquinolones, Foot, Humans, leprosy, Male, Mice, Middle Aged, Moxifloxacin, Mycobacterium leprae, Quinolines, Skin, Treatment Outcome},
  author = {Pardillo FE and Burgos J and Fajardo TT and Dela Cruz E and Abalos R and Paredes RM and Andaya CE and Gelber R},
  title = {Powerful bactericidal activity of moxifloxacin in human leprosy.},
  abstract = {<p>In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.</p>},
  year = {2008},
  journal = {Antimicrobial agents and chemotherapy},
  volume = {52},
  pages = {3113-7},
  month = {2008 Sep},
  issn = {1098-6596},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533472/pdf/1162-07.pdf},
  doi = {10.1128/AAC.01162-07},
  language = {eng},
}